Tag: disease modifying therapies
Successful advocacy results in cladribine access for Iran
Adding MS treatments to the WHO Essential Medicines List leads to real-world benefit
The challenge of accessing MS treatment in Yemen
The Yemeni Association for the Care of Multiple Sclerosis Patients fights for treatment for people with MS
People with MS in Albania given new hope with widening access to MS treatment
Fondacioni Pema e Jetës (Tree of Life Foundation) successfully advocated for reimbursed access to MS treatments
MSIF puts a spotlight on the ethical use of off-label disease modifying therapies for MS
New publication from MSIF on ethical use of off-label DMTs receives global endorsement
How different disease modifying therapies can delay progression
A new study examined different disease modifying therapies and their ability to slow the onset of secondary progressive MS.
Study suggests improvement in MS employment outcomes
New research, involving 874 people who had used disease-modifying therapies during the previous 5 years, has shown a link between more effective disease-modifying therapies and an increased level of employment, work attendance and productivity at work.